SNSE - Sensei Biotherapeutics, Inc.

30
-0.500   -1.667%

Share volume: 117,584
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.14%

PREVIOUS CLOSE
CHG
CHG%
$30.50
-0.50
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
37%
Profitability 35%
Dept financing 22%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
3.45%
1 Month
240.52%
3 Months
264.08%
6 Months
278.32%
1 Year
6,942.25%
2 Year
2,870.30%
Key data
Stock price
$30.00
P/E Ratio 
0.00
DAY RANGE
$29.77 - $31.56
EPS 
-$4.48
52 WEEK RANGE
$0.25 - $36.76
52 WEEK CHANGE
$6,942.25
MARKET CAP 
11.919 M
YIELD 
N/A
SHARES OUTSTANDING 
1.261 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
1.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$144,421
AVERAGE 30 VOLUME 
$766,650
Company detail
CEO: John K. Celebi
Region: US
Website: senseibio.com
Employees: 40
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Sensei Biotherapeutics, Inc. engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer.

Recent news